| TRANSGENE SA EO 0,30 |
| Frankreich |
| Gesundheit |
| FR0005175080 / 913048 |
| TGNA (Frankfurt) |
| FRA:TGNA, ETR:TGNA, TGNA:GR |
| - |
| http://www.transgene.fr/ |
|
Transgene SA is a French clinical-stage biotechnology company specializing in the development of virus-based immunotherapies for cancer and infectious diseases. Headquartered in Illkirch-Graffenstaden near Strasbourg and founded in 1979, it harnesses..
>Volltext.. |
| 209.72 Mio. EUR |
| 99.97 Mio. EUR |
| 0.14 Mio. EUR |
| -39.82 Mio. EUR |
| -38.18 Mio. EUR |
| -0.26 EUR |
| 2.09 Mio. EUR |
| 6.77 Mio. EUR |
| -37.38 Mio. EUR |
| 9.14 |
| 291.43% |
| -10.46% |
| - |
| - |
| - |
| - |
| TRANSGENE |
| 05.04.26 |
|